Search results for "Cooking"

showing 10 items of 635 documents

Impact of Accessory Renal Artery Coverage on Renal Function during Endovascular Aortic Aneurysm Repair.

2021

Background Long-term outcomes of accessory renal artery (ARA) coverage after endovascular aneurysm repair (EVAR) are unknown. We analyzed the impact of ARA coverage on renal function long-term. Methods This retrospective, monocentric study included patients treated by EVAR between 2008 and 2016. Patients with at least one ARA covered with EVAR (ARA group) were compared with patients with no covered ARA (control group). Renal function was determined by estimating the glomerular filtration rate (eGFR) and graded according to chronic kidney disease (CKD) classification stages. Results A total of 184 patients were included (ARA group, n = 25; control group, n = 159). Renal risk factors were sim…

Malemedicine.medical_specialtyTime FactorsRenal infarctionmedicine.medical_treatmentUrologyRenal function030204 cardiovascular system & hematologyKidneyEndovascular aneurysm repair030218 nuclear medicine & medical imagingAccessory renal artery03 medical and health sciencesBlood Vessel Prosthesis Implantation0302 clinical medicineRenal ArterymedicineHumansStage (cooking)Renal Insufficiency ChronicSuprarenal fixationAgedRetrospective StudiesAged 80 and overAortic aneurysm repairbusiness.industryEndovascular Proceduresfood and beveragesGeneral Medicinebiochemical phenomena metabolism and nutritionmedicine.diseaseAortic AneurysmBlood Vessel Prosthesiscarbohydrates (lipids)Treatment OutcomeDisease ProgressionSurgeryFemaleCardiology and Cardiovascular MedicinebusinessKidney diseaseGlomerular Filtration RateAnnals of vascular surgery
researchProduct

Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective cohort study.

2014

Few studies describe the effect of non-muscle-invasive bladder cancer (NMIBC) on health-related quality of life (HRQL), although patients are mostly diagnosed at this stage of the disease. Taking into account this current evidence gap and the high incidence rates in Spain, we aimed to describe the evolution over time of HRQL in Spanish patients with NMIBC and to examine the clinical and treatment-related factors associated with HRQL change during the first year of management.Observational multicenter prospective inception cohort study conducted in urology departments of 7 Spanish hospitals. A consecutive sample of 244 patients with anatomopathologically confirmed NMIBC, recruited from Octob…

Malemedicine.medical_specialtyUrologyUrinary systemDiseaseCohort StudiesQuality of lifeInternal medicinemedicineHumansProspective StudiesStage (cooking)Prospective cohort studyGeneralized estimating equationAgedNeoplasm StagingBladder cancerbusiness.industrymedicine.diseasehumanitiesOncologyUrinary Bladder NeoplasmsPhysical therapyQuality of LifeObservational studyFemalebusinessUrologic oncology
researchProduct

Stage and Grade Migration in Prostate Cancer Treated With Radical Prostatectomy in a Large German Multicenter Cohort.

2020

Abstract Introduction Overdiagnosis and overtherapy in prostate cancer (PCa) treatment should be avoided, which has led to an awareness of the need to decrease treatment in cases of low-risk PCa with radical prostatectomy (RP). Simultaneously, prostate-specific antigen testing has become less popular in the last few years, which has resulted in higher cancer grade and stage at diagnosis. We evaluated stage and grade migration in the disease of patients treated with RP in a large German cohort. Patients and Methods Overall, 4842 patients undergoing RP between 2000 and 2019 were included. Age, prostate-specific antigen level, biopsy, and pathologic Gleason score as well as clinical and pathol…

Malemedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyUrology03 medical and health sciencesProstate cancer0302 clinical medicineRisk groupsBiopsymedicineHumansOverdiagnosisStage (cooking)Neoplasm StagingProstatectomymedicine.diagnostic_testProstatectomybusiness.industryCancerProstatic NeoplasmsProstate-Specific Antigenmedicine.disease3. Good healthOncology030220 oncology & carcinogenesisCohortNeoplasm GradingbusinessClinical genitourinary cancer
researchProduct

Coincident vesical transitional cell carcinoma and prostatic carcinoma. Clinical features and treatment.

1986

Summary— Twenty-two patients with vesical urothelial carcinoma associated with prostatic carcinoma were reviewed. They represented 1.5% of the bladder and prostatic tumours treated in our department within a 12-year period from 1968 to 1979. Their management included several treatment policies, based on the separate assessment of each tumour variant. For non-infiltrating bladder tumours, transurethral tumour resection was combined with hormonal treatment, external radiotherapy or resection of the prostate depending on the stage of the prostatic tumour. Radical cystoprostatectomy was performed for two cases of infiltrating bladder tumour with well localised prostatic tumours. A conservative …

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentTumor resectionUrologyCystoprostatectomyNeoplasms Multiple PrimaryProstatemedicineCarcinomaHumansNeoplasm InvasivenessStage (cooking)PathologicalAgedCarcinoma Transitional Cellbusiness.industryCancerProstatic NeoplasmsMiddle Agedmedicine.diseasePrognosismedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsbusinessBritish journal of urology
researchProduct

Surgery in rhabdomyosarcoma of the bladder, prostate and vagina

1995

The treatment of bladder and prostate rhabdomyosarcoma (RMS) is highly controversial. Aside from chemotherapy, treatment modalities include conservative surgery, radical surgery, and pre-, intra-, or postoperative irradiation. Between 1968 and 1993, 78 children with RMS were treated at our institution. In all, 22 tumors were located in the urogenital tract (bladder/prostate, 13; paratesticular, 5; vaginal, 2; others, 2). Altogether, 6 patients had stage II disease; 7, stage III disease; and 2, stage IV disease. All 15 patients with RMS of the bladder, prostate, or vagina received chemotherapy, and 4 had additional radiotherapy. Surgery was also done in 10 patients; parents refused an operat…

Malemedicine.medical_specialtyVaginal NeoplasmsAdolescentUrologymedicine.medical_treatmentProstate RhabdomyosarcomaVaginal diseaseProstateAntineoplastic Combined Chemotherapy ProtocolsRhabdomyosarcomamedicineHumansRadical surgeryStage (cooking)ChildRhabdomyosarcomaRetrospective StudiesUrinary bladderbusiness.industryInfantProstatic Neoplasmsmedicine.diseaseSurgeryRadiation therapyTreatment Outcomemedicine.anatomical_structureUrinary Bladder NeoplasmsChild PreschoolFemalebusinessFollow-Up StudiesWorld Journal of Urology
researchProduct

Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer

2016

Abstract Background The most common presenting symptom of bladder cancer (BCa) is hematuria. The present study was designed to define whether patients taking antiplatelet and/or anticoagulant drugs might experience hematuria at an earlier stage or grade of BCa. Patients and Methods The data from 1532 consecutive patients who presented to the emergency unit of our institute from 2004 to 2012 because of gross hematuria as a single symptom were evaluated. Patients (n = 227) with a further diagnosis of BCa were included in our study. For the purpose of the present study, patients were divided into 2 groups: patients receiving antiplatelet or anticoagulant therapy (AAT) (group 1) and patients no…

Malemedicine.medical_specialtymedicine.drug_classUrology030232 urology & nephrologyLogistic regressionSettore MED/24 - Urologia03 medical and health sciences0302 clinical medicineRetrospective StudieInternal medicinemedicineHumansAntiplateletStage (cooking)Macroscopic hematuriaAnticoagulant; Antiplatelet; Bladder cancer; Emergency room; Hematuria; Non-muscle invasive bladder cancerEarly Detection of CancerRetrospective StudiesHematuriaAgedNeoplasm StagingBladder cancerbusiness.industryPlatelet Aggregation InhibitorAnticoagulantBladder cancerAnticoagulantAnticoagulantsRetrospective cohort studyEmergency roomOdds ratioMiddle Agedmedicine.diseaseSurgeryUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisUrinary Bladder NeoplasmPlatelet aggregation inhibitorFemalebusinessNon-muscle invasive bladder cancerPlatelet Aggregation InhibitorsHuman
researchProduct

Prediction by quantitative histology of pathological stage in prostate cancer.

2005

To find a predictor of extraprostatic extension in clinically localized prostate cancer (PCa), pre-operative ultrasound-guided prostate needle biopsies and clinico-pathological data were reviewed.One hundred and eighty-three consecutive patients who underwent radical retropubic prostatectomy for clinical T1-T2 PCa and serum PSA10 ng/ml were reviewed. Pre-operative biopsy was performed according to an extended protocol and whole-mount prostatectomy specimens were processed. The following biopsy variables were categorized to this analysis: Gleason score (or =6,6), TPC (or =20%;20%), GPC (or =50%;50%), cancer-positive cores (or =2;2), cancer-positive cores in both lateral portions (yes; no), P…

Malemedicine.medical_specialtymedicine.medical_treatmentBiopsyUrologyurologic and male genital diseasesLogistic regressionSensitivity and SpecificityProstate cancerProstatePredictive Value of TestsBiopsymedicineOdds RatioHumansStage (cooking)AgedNeoplasm Stagingmedicine.diagnostic_testbusiness.industryProstatic NeoplasmsGeneral MedicineOdds ratioMiddle AgedProstate-Specific Antigenmedicine.diseaseSurgerymedicine.anatomical_structureLogistic ModelsOncologyROC CurveMultivariate AnalysisSurgeryPositive Surgical MarginbusinessRadical retropubic prostatectomyEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Exposed necrotic bone in 183 patients with bisphosphonate-related osteonecrosis of the jaw: Associated clinical characteristics

2017

The main objective of our study was to identify oral symptoms and signs most likely to be associated with the exposure of necrotic bone in bisphosphonate-related osteonecrosis of the jaw (BRONJ). The study group consisted of 183 patients with BRONJ. We recorded data on the underlying disease, bisphosphonate used, location of osteonecrosis, symptoms, pain, fistula development, suppuration, infection, exposed necrotic bone, and BRONJ stage. The mean age of the patients was 68.22 ± 12.19 years. The sample included 118 (64.5%) women. Breast cancer and multiple myeloma were the most common underlying diseases, and 50 patients received oral bisphosphonates for osteoporosis. Dental extractions (69…

Malemedicine.medical_specialtymedicine.medical_treatmentFistulaOsteoporosisOdontologíaMaxilares03 medical and health sciencesNecrosis0302 clinical medicineBreast cancermedicineHumansStage (cooking)General DentistryMultiple myelomaUNESCO:CIENCIAS MÉDICASAgedRetrospective StudiesOral Medicine and Pathologybusiness.industryResearchRetrospective cohort study030206 dentistryBisphosphonatemedicine.diseaseSurgeryOtorhinolaryngology030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleSurgerySymptom AssessmentOsteonecrosis of the jawbusiness
researchProduct

Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis

2016

OBJECTIVE: To describe the clinical characteristics and evolution of our series of medication-related osteonecrosis of the jaws (MRONJ) associated with denosumab in osteoporotic patients. MATERIAL AND METHODS: We present 10 new cases of MRONJ in patients receiving denosumab for osteoporosis. We describe the mean doses of denosumab, previous bisphosphonate intake, and the clinical characteristics associated with the osteonecrosis, such as local contributing factors, symptoms, and evolution after treatment. RESULTS: The mean number of denosumab doses was 3.4 2.2. In 90% of patients, there was a prior history of oral bisphosphonate intake, with a mean duration of 46.78 25.11 months. The most c…

Malemedicine.medical_specialtymedicine.medical_treatmentOsteoporosisDentistryOdontología03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansStage (cooking)General DentistryAgedSclerosisMedicamentoBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industry030206 dentistryMiddle AgedBisphosphonatemedicine.diseaseBone Density Conservation AgentsDenosumabOtorhinolaryngologyDental extraction030220 oncology & carcinogenesisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemaleDenosumabTomography X-Ray ComputedOsteonecrosis of the jawbusinessmedicine.drugOral Diseases
researchProduct

Polyphenol intake and mortality risk: a re-analysis of the PREDIMED trial

2014

[Background] Polyphenols may lower the risk of cardiovascular disease (CVD) and other chronic diseases due to their antioxidant and anti-inflammatory properties, as well as their beneficial effects on blood pressure, lipids and insulin resistance. However, no previous epidemiological studies have evaluated the relationship between the intake of total polyphenols intake and polyphenol subclasses with overall mortality. Our aim was to evaluate whether polyphenol intake is associated with all-cause mortality in subjects at high cardiovascular risk.

MaleriesgoMediterranean dietmodelos de riesgos proporcionaleshumanosPhysiologyDiet MediterraneanAntioxidantsRisk FactorsSistema cardiovascular--MalaltiesCause of DeathNeoplasmsflavonoidesEpidemiologyStilbenesHydroxybenzoates1741-7015mediana edadCause of deathAged 80 and overMedicine(all)neoplasiasancianodietaHazard ratiofood and beveragesGeneral MedicineMiddle AgedCardiovascular diseaseAll-cause mortalityMetabolismeCardiovascular DiseasesPolifenolsFemaleResearch ArticleRiskPREDIMEDmedicine.medical_specialtyenfermedades cardiovascularesLignansInsulin resistanceMediterranean cookingMedical statisticscausas de muertehidroxibenzoatosMediterranean dietCuina mediterràniaantioxidantesmedicineMortalitatHumansfactores de riesgoFood consumptionMortalitypolifenolesAgedProportional Hazards ModelsFlavonoidsProportional hazards modelbusiness.industryPolyphenolsPREDIMED studyPolyphenol intakemedicine.diseaseConfidence intervalBiotechnologyDietMetabolismPolyphenolCommentarybusinessEstadística mèdicaConsum d'aliments
researchProduct